AVDL vs. ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, APLS, and BHVN
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs.
Alvotech (NASDAQ:ALVO) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.
Avadel Pharmaceuticals has a net margin of -52.53% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Avadel Pharmaceuticals' return on equity.
Alvotech currently has a consensus price target of $18.00, indicating a potential upside of 88.48%. Avadel Pharmaceuticals has a consensus price target of $19.88, indicating a potential upside of 148.13%. Given Avadel Pharmaceuticals' higher possible upside, analysts clearly believe Avadel Pharmaceuticals is more favorable than Alvotech.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 0.5% of Alvotech shares are held by insiders. Comparatively, 4.8% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Alvotech has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Avadel Pharmaceuticals has lower revenue, but higher earnings than Alvotech. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals received 342 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 66.48% of users gave Avadel Pharmaceuticals an outperform vote while only 50.00% of users gave Alvotech an outperform vote.
In the previous week, Alvotech had 17 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 21 mentions for Alvotech and 4 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 0.85 beat Alvotech's score of 0.76 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media.
Summary
Avadel Pharmaceuticals beats Alvotech on 11 of the 17 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy AVDL Stock Free AVDL Stock Alerts